Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
申请人:Edwards Louise
公开号:US20050272779A1
公开(公告)日:2005-12-08
The present invention relates to new compounds of formula I,
to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
Rhodium-catalyzed heterocycloaddition route to 1,3-oxazoles as building blocks in natural products synthesis
作者:Richard D. Connell、Mark Tebbe、Anthony R. Gangloff、Paul Helquist、Björn Åkermark
DOI:10.1016/s0040-4020(01)87261-6
日期:——
Rhodium(II) acetate serves as a catalyst for the heterocycloaddition reaction of diazodicarbonyl compounds with nitriles to give functionalized 1,3-oxazole derivatives in a simple one-step procedure. In particular, dimethyl diazomalonate undergoes this reaction to give 2-aryl-, 2-alkenyl-, or 2-alkyl-4-carbomethoxy-5-methoxy-1,3-oxazoles, and ethyl formyldiazoacetate (diazomalonate half-ester half-aldehyde)
The present invention relates to new compounds of formula I,
a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
申请人:Edwards Louise
公开号:US20080045571A1
公开(公告)日:2008-02-21
The present invention relates to new compounds of formula I,
to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists
申请人:Edwards Louise
公开号:US20080312246A1
公开(公告)日:2008-12-18
The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof:
where Ar
1
, Ar
2
, Hy, L, R
1
, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.